These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1624678)

  • 1. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome.
    Sherman SI; Ladenson PW
    J Endocrinol Invest; 1992 Mar; 15(3):185-90. PubMed ID: 1624678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acromegaly associated with McCune-Albright syndrome].
    Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
    Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome.
    Cuttler L; Jackson JA; Saeed uz-Zafar M; Levitsky LL; Mellinger RC; Frohman LA
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1148-54. PubMed ID: 2498385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acromegaly, multinodular goiter and silent polyostotic fibrous dysplasia. A variant of the McCune-Albright syndrome.
    Abs R; Beckers A; Van de Vyver FL; De Schepper A; Stevenaert A; Hennen G
    J Endocrinol Invest; 1990 Sep; 13(8):671-5. PubMed ID: 2273209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995--bromocriptine combined treatment results.
    Cremonini N; Graziano E; Chiarini V; Sforza A; Zampa GA
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1166-9. PubMed ID: 1400888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases.
    Chanson P; Dib A; Visot A; Derome PJ
    Eur J Endocrinol; 1994 Sep; 131(3):229-34. PubMed ID: 7921205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
    Almeida JP; Albuquerque LA; Ferraz CL; Mota I; Gondim J; Ferraz TM
    Arq Bras Endocrinol Metabol; 2009 Feb; 53(1):102-6. PubMed ID: 19347192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acromegaly and hyperprolactinemia in McCune-Albright syndrome. Evidence of hypothalamic dysfunction.
    Chung KF; Alaghband-Zadeh J; Guz A
    Am J Dis Child; 1983 Feb; 137(2):134-6. PubMed ID: 6401383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. McCune-Albright syndrome: growth hormone and prolactin hypersecretion.
    Christoforidis A; Maniadaki I; Stanhope R
    J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():623-5. PubMed ID: 16789626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. McCune-Albright syndrome with gigantism and hyperprolactinemia.
    Pacini F; Perri G; Bagnolesi P; Cilotti A; Pinchera A
    J Endocrinol Invest; 1987 Aug; 10(4):417-20. PubMed ID: 3680873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome.
    Geffner ME; Nagel RA; Dietrich RB; Kaplan SA
    J Pediatr; 1987 Nov; 111(5):740-3. PubMed ID: 2889819
    [No Abstract]   [Full Text] [Related]  

  • 12. Gigantism and hyperprolactinemia in polyostotic fibrous dysplasia (Mc Cune--Albright syndrome).
    Polychronakos C; Tsoukas G; Ducharme JR; Letarte J; Collu R
    J Endocrinol Invest; 1982; 5(5):323-6. PubMed ID: 7153476
    [No Abstract]   [Full Text] [Related]  

  • 13. McCune-Albright Syndrome in Infant with Growth Hormone Excess.
    Brzica K; Simunovic M; Ivancic M; Tudor D; Skrabic I; Skrabic V
    Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 36011254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric management of endocrine complications in McCune-Albright syndrome.
    Zacharin M
    J Pediatr Endocrinol Metab; 2005 Jan; 18(1):33-41. PubMed ID: 15679067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
    Tajima T; Tsubaki J; Ishizu K; Jo W; Ishi N; Fujieda K
    Endocr J; 2008 Jul; 55(3):595-9. PubMed ID: 18445999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
    Garcia MB; Koppeschaar HP; Lips CJ; Thijssen JH; Krenning EP
    J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis.
    Kovacs K; Horvath E; Thorner MO; Rogol AD
    Virchows Arch A Pathol Anat Histopathol; 1984; 403(1):77-86. PubMed ID: 6426154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gigantism with pituitary macroadenoma: an unusual variant of McCune-Albright syndrome.
    Queirolo S; Gallarotti F; Capuano E; Garrè ML; Spaziante R; Di Battista E
    J Pediatr Endocrinol Metab; 2009 Feb; 22(2):177-9. PubMed ID: 19449675
    [No Abstract]   [Full Text] [Related]  

  • 19. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy.
    Chen CC; Czerwiec FS; Feuillan PP
    J Nucl Med; 1998 Feb; 39(2):238-40. PubMed ID: 9476926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome.
    Akintoye SO; Kelly MH; Brillante B; Cherman N; Turner S; Butman JA; Robey PG; Collins MT
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2960-6. PubMed ID: 16720661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.